Authors

Eric Jonasch, MD, University of Texas MD Anderson Cancer Center

Latest:

Selecting Optimal Therapy for Advanced Non-Clear Cell RCC

Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.

Eric Klein, MD

Latest:

Dr. Klein on the Rationale to Evaluate VERU-111 in mCRPC

Eric Klein, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.

Eric Larsen, MD

Latest:

Dr. Larsen Discusses Outcomes for AYA ALL Patients

Dr. Eric Larsen, from the Maine Children's Cancer Program, Discusses Outcomes for AYA Patients With Acute Lymphoblastic Leukemia

Eric Liu, MD, FACS

Latest:

Dr. Liu on Medical Advancements for Neuroendocrine Tumors

Eric Liu, MD, FACS, surgeon, neuroendocrine tumors, Rocky Mountain Cancer Centers, discusses some of the most recent medical advancements in the field of neuroendocrine tumors.

Eric Liu, MD, FACS, Rocky Mountain Cancer Centers

Eric M. Horwitz, MD

Latest:

Dr. Horwitz on the Evolution of Radiation Therapy in Prostate Cancer

Eric M. Horwitz, MD, FABS, FASTRO, discusses the evolution of radiation therapy in prostate cancer.

Eric M. Ostertag, MD, PhD

Latest:

Dr. Ostertag on Emerging CAR T Product for Myeloma

Eric M. Ostertag, MD, PhD, chief executive officer, Poseida Therapeutics, Inc., discusses an emerging CAR T stem cell memory product for patients with relapsed/refractory multiple myeloma.

Eric Padron, MD

Latest:

Dr. Padron on the SRSF2 Mutation in MDS and CMML

Eric Padron, MD, discusses the SRSF2 mutation in patients with MDS and CMML.

Eric Pujade-Lauraine, MD, PhD

Latest:

Dr. Pujade-Lauraine on the AURELIA Bevacizumab Trial

Dr. Eric Pujade-Lauraine, from UniversitÃ© de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.

Eric Roeland, MD, UC San Diego Health

Eric Roeland, MD, University of California, San Diego

Eric S. Nadler, MD

Latest:

Dr. Nadler on the Impact of Immunotherapy in Squamous NSCLC

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the impact of immunotherapy in squamous non–small cell lung cancer.

Eric Shinohara, MD, MSCI

Latest:

Dr. Shinohara on Pairing SBRT With Immunotherapy in Prostate Cancer

Eric Shinohara, MD, MSCI, discusses the potential to combine stereotactic body radiotherapy with immunotherapy in prostate cancer.

Eric Smith, MD, PhD

Latest:

Dr. Smith Discusses CAR T Cell Persistence in Myeloma

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.

Eric Stephen Winer, MD

Latest:

Dr Winer on the Rationale for the TakeAim Leukemia Trial in Mutated AML

Eric Winer, MD, discusses the rationale for the phase 1/2a TakeAim Leukemia trial of emavusertib in patients with R/R FLT3- and spliceosome-mutated AML.

Eric T. Wong, MD

Latest:

Dr. Wong Discusses Recent Negative Trials in Glioblastoma

Eric T. Wong, MD, associate professor of neurology at Harvard Medical School and co-director of the Brain Tumor Center at Beth Israel Deaconess Medical Center, discusses recent negative trials in glioblastoma.

Eric Vallieres, MD

Latest:

Dr Vallieres on the Role of Induction Therapy on Surgical Candidacy in Lung Cancer

Eric Vallieres, MD, FRCSC, discusses the impact of induction therapy on surgical candidacy and operative complexity in patients with thoracic malignancies.

Eric Van Cutsem, MD, PhD

Latest:

Dr. Van Cutsem on Primary Findings from the SPOTLIGHT and GLOW Trials in Metastatic Gastric Cancer

Eric Van Cutsem, MD, PhD, discusses primary efficacy and safety findings from the phase 3 SPOTLIGHT and GLOW trials investigating the monoclonal antibody zolbetuximab in metastatic gastric cancer.

Eric Van Cutsem, MD, PhD, University of Leuven

Eric Whitman, MD

Latest:

Dr. Whitman on Expanding the Benefit of Immunotherapy in Solid Tumors

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.